Re: Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study was written by Altundag, Kadri. And the article was included in European Journal of Cancer in 2022.SDS of cas: 571190-30-2 This article mentions the following:
A polemic in response to Martin et al. (Eur J Cancer 2022;168:12e24) is given. In a recent publication by Martin et al. concluded that Overall survival with palbociclib plus endocrine therapy vs. capecitabine in postmenopausal patients with hormone receptor-pos., HER2-neg. metastatic breast cancer. Specifically, the visceral metastatic burden was not described. It would be expected that tumors with a higher visceral tumor burden are less likely to be responsive to treatment. Second, weak estrogen receptor status (close similarity to triple-neg. breast cancer) has not been reported. The author concluded that these tumors seem to be more likely to be responsive to capecitabine than the palbociclib combination. In the experiment, the researchers used many compounds, for example, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (cas: 571190-30-2SDS of cas: 571190-30-2).
6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (cas: 571190-30-2) belongs to piperazine derivatives. Piperazine belongs to the family of medicines called anthelmintics. Piperazine is an anthelminthic especially useful in the treatment of partial intestinal obstruction caused by Ascaris worms, which is a condition primarily seen in children. Piperazine hydrate and piperazine citrate are the main anthelminthic piperazines.SDS of cas: 571190-30-2
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics